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Introduction
Epidemiological and experimental evidence implicates
oestrogens in the aetiology of breast cancer. Most estab-
lished risk factors for breast cancer in humans are thought
to influence risk through hormone-related pathways [1],
increased concentrations of endogenous oestrogens are
strongly associated with increased risk for breast cancer
in postmenopausal women [2], and trials have shown that
the anti-oestrogens tamoxifen and raloxifene reduce the
incidence of breast cancer [3]. Furthermore, experimental
studies in animals have shown that oestrogens can
promote mammary tumours, and a decrease in exposure
to oestrogens, by performing an oophorectomy or giving
an anti-oestrogenic drug, has the reverse effect [4].
However, the effects of oestrogen alone do not fully
account for the relationships observed between breast
cancer and hormone-related risk factors. Other hormones,
such as progesterone [1], prolactin [5] and testosterone
[6], may also be important.
This article explores the evidence for the hypothesis that
exposure to oestrogen is a major determinant of risk for
breast cancer. It is not intended to be a comprehensive
review but rather focuses on recent epidemiological and
experimental data relating to the role of oestrogen in the
aetiology of breast cancer and possible mechanisms that
might account for the association. There are several forms
of oestrogen, the principal form in humans being oestra-
diol, but for convenience in this article we refer generally
to oestrogens except where it is necessary to be more
specific.
Reproductive risk factors, oestrogen and
breast cancer
Oestrogens have an essential role, together with other
hormones, in the development of the female sex organs
and secondary sex characteristics, the regulation of the
menstrual cycle and reproduction. Thus, it has been pro-
posed that the effects of many established reproductive
risk factors for breast cancer are mediated by hormonal
mechanisms, for the most part involving oestrogens [1].
Although risk for breast cancer increases with age, there
is a marked decline in the rate of increase in risk with age
following the loss of ovarian function, either as a result of a
bilateral oophorectomy or due to the menopause [7,8],
showing that hormone production by the ovaries is a
crucial risk factor for breast cancer in humans. The
duration of exposure to ovarian hormones seems to be
closely related to breast cancer risk: a 1-year delay in the
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Abstract
Epidemiological and experimental evidence implicates oestrogens in the aetiology of breast cancer.
Most established risk factors for breast cancer in humans probably act through hormone-related
pathways, and increased concentrations of circulating oestrogens have been found to be strongly
associated with increased risk for breast cancer in postmenopausal women. This article explores the
evidence for the hypothesis that oestrogen exposure is a major determinant of risk for breast cancer.
We review recent data on oestrogens and breast cancer risk, consider oestrogen-related risk factors
and examine possible mechanisms that might account for the effects of oestrogen. Finally, we discuss
how these advances might influence strategies for reducing the incidence of breast cancer.
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onset of menarche is associated with a 5% reduction in
risk for developing breast cancer in later life [9], and each
1-year delay in the onset of menopause is associated with
a 3% increase in risk [7].
Epidemiological studies have also firmly established asso-
ciations between risk for breast cancer and other repro-
ductive factors, including nulliparity (having no children) or
low parity, late age at first birth, and breast feeding [10].
After a transient increase in risk for breast cancer, peaking
at about 5 years after giving birth [11], having at least one
child is associated with a decrease in the long-term risk of
developing breast cancer compared with risk among the
nulliparous, and this protective effect increases with
number of children [12]. Each birth reduces the relative
risk of breast cancer by an average of 7% [12]. The reduc-
tion in risk per birth is greater for births at young ages than
older ages, such that women who have their first birth
before the age of 20 years have a 30% lower risk than
women with a first birth after the age of 35 years [13].
A mechanism involving oestrogens, and probably other
hormones, has been proposed to explain both the tran-
sient increase in risk and the reduced risk in the long term
associated with pregnancy. The very high serum levels of
oestrogens and progesterone during pregnancy stimulate
growth of the mammary epithelium and also promote the
differentiation of epithelial tissue, reducing the number of
epithelial structures most vulnerable to malignant transfor-
mation [14]. Thus, the short-term effect of pregnancy may
be to promote the growth of cancer if a malignant transfor-
mation is present in the breast, but in the longer term the
risk for breast cancer is reduced. In contrast, malignant
transformations are more likely to have accumulated in the
breast tissue of older women, and there might therefore
be a higher risk of cancer developing in these women
when breast cells are stimulated to divide during preg-
nancy. The effect of age at first birth highlights the impor-
tance of timing of exposure as a critical determinant of the
effects of steroid hormones such as oestrogen.
Breast feeding is associated with a modest decrease in
risk for breast cancer, above and beyond that associated
with multiple pregnancies (4% for every 12 months of
breast feeding) [12]. This effect might be due to the sup-
pression of ovulation, reducing exposure to ovarian hor-
mones.
Diet-related and lifestyle factors in relation to
breast cancer
Two diet-related factors, high alcohol intake [15] and
obesity [16], are established risk factors for breast cancer.
A moderate intake of alcohol (one unit a day) increases
risk by 7%, and higher intakes of alcohol increase risk in
an approximately linear fashion. The mechanism for this
effect remains unknown but has been proposed to involve
increased concentrations of circulating oestrogens
[15,17]. Breast cancer risk among postmenopausal
women is also strongly associated with body mass index
(BMI, an index of body weight independent of height, cal-
culated as body weight in kilograms divided by the square
of the height measured in metres). Risk for breast cancer
is increased by 30% among obese postmenopausal
women (with a BMI of more than 30kg/m2) compared with
those with a normal BMI (less than 25kg/m2) [16]. This
association is probably due to the relationship between
BMI and endogenous oestrogen concentrations because,
in postmenopausal women, circulating oestrogen concen-
trations are dependent on the extraglandular production of
oestrogen in the adipose tissue.
For premenopausal women, the lack of a positive associa-
tion of BMI with breast cancer risk [16] is consistent with
the facts that most oestrogen is produced by the ovaries
and that levels are homeostatically regulated by a negative
feedback system involving gonadotrophins (follicle-stimu-
lating hormone and luteinising hormone). Thus, oestrogen
concentrations in premenopausal women are not directly
affected by the levels of adipose tissue. Indeed, obesity in
premenopausal women has been linked to a slight
decrease in risk for breast cancer [16], possibly mediated
through an increase in the occurrence of anovulatory
cycles and a subsequent decrease in exposure to ovarian
progesterone among these women (see below). It has
been suggested that this decrease in breast cancer risk
due to obesity in early adulthood may continue into later
life, negating some of the increased risk of breast cancer
among women who remain obese after the menopause
[18]. Evidence for this comes from the finding that weight
gain from adolescence to adulthood is most strongly and
consistently associated with risk of postmenopausal
breast cancer [16], with weight gains of over 20kg asso-
ciated with an increase in risk of 40% [19].
Physical activity has also been observed to be associated
with a reduced risk for breast cancer in both pre-
menopausal and postmenopausal women. Most studies
have found a 20–40% decrease in risk of breast cancer
among the most physically active [16]. The effects of
physical activity on breast cancer risk may be mediated
through alterations in endogenous hormones including
oestrogens, energy balance, body mass and possibly
immune function [20]. In postmenopausal women this low
risk might be due in part to physical activity preventing
weight gain and obesity [20], although there is some evi-
dence to suggest that the effects of physical activity are
independent of weight control [21]. In premenopausal
women the effects of high levels of physical exercise may
be mediated by other mechanisms [20]. For example,
there is considerable evidence that intense physical activ-
ity can alter menstrual cycle characteristics, delay men-
arche and increase the probability of anovulatory cycles,241
amenorrhoea or oligomenorrhoea, thus reducing exposure
to ovarian hormones [20,22–24], and there is also some
promising evidence that even moderate exercise may be
beneficial [25–27].
Endogenous oestrogens and breast cancer in
humans
Direct evidence for a relationship between oestrogens and
risk of developing breast cancer comes from observational
studies that have found circulating and excreted oestro-
gen levels to be associated with risk for the disease [28].
Because breast cancer itself might affect hormone pro-
duction, it is necessary to conduct prospective studies of
oestrogens and breast cancer risk in which samples are
collected at the start of the study from healthy women,
who are then followed up with respect to cancer diag-
noses. Such investigations have considered pre-
menopausal and postmenopausal women separately
because the endogenous production of and exposure to
endogenous oestrogen varies greatly during a woman’s
lifespan. In premenopausal women, the predominant form
of circulating oestrogen is oestradiol secreted by the
ovaries in cyclical monthly patterns. After the menopause,
however, the production of oestrogens in the ovaries
ceases and the major source of oestradiol is by conver-
sion from oestrone, itself produced mostly through the
peripheral conversion of androgen precursors, predomi-
nantly androstenedione, in extraglandular tissue such as
adipose tissue [29].
A recent pooled analysis of nine prospective studies in
postmenopausal women, including 663 breast cancer
cases, found a highly significant increase in breast cancer
risk with increasing concentrations of oestradiol, free
oestradiol and oestrone in the blood [2]. Postmenopausal
women with relatively high serum oestrogen concentra-
tions had an approximately twofold risk of breast cancer
compared with postmenopausal women with relatively low
serum concentrations of sex hormones [2]. Studies have
also evaluated the relationship between urinary endoge-
nous oestrogens and breast cancer; recent results from
the largest prospective study of oestrogens and breast
cancer found women with a higher excretion of oestrone
and oestradiol to have a significantly increased risk for
breast cancer [30].
Data on oestrogen levels in premenopausal women and
breast cancer risk are sparse, with only five small prospec-
tive studies published so far [31–35]. Of the three larger
and more recent studies, two found a nonsignificant
increase in mean oestradiol concentrations among cases
in comparison with controls [33,34], and the third
reported significantly elevated levels of bioavailable
oestradiol and a nonsignificant increase in total oestradiol
in cases [35]. These results are compatible with the
oestrogen hypothesis, but the numbers studied are too
small, and the difficulties of appropriate adjustment for day
of menstrual cycle too complex, to allow any firm conclu-
sions.
A limitation with all these studies is that they rely on meas-
urements made from just one sample, and whereas meas-
urements in single samples from postmenopausal women
have been found to be fairly representative of long-term
circulating oestrogen concentrations, single sample mea-
surements from premenopausal women are less represen-
tative of average circulating concentrations [36,37]. The
reliable estimation of circulating oestrogen concentrations
in premenopausal women is complicated by the fluctuat-
ing levels of oestrogen over the course of the menstrual
cycle, such that the timing of the sample is a strong deter-
minant of the oestrogen concentration measured.
Binding proteins and the bioavailability of
oestrogens
The availability of oestrogen in tissues is determined not
only by the production of the hormone and concentrations
in circulation but also by the extent to which it is bound to
a binding protein, sex-hormone-binding globulin (SHBG).
Thus, high concentrations of SHBG decrease the propor-
tion of oestradiol that is able to leave the circulation and
enter the cells. SHBG might partly mediate the effects of
obesity in postmenopausal women because obesity is
associated with lower levels of SHBG [36] and an inverse
association has been observed between concentrations of
SHBG and breast cancer risk in postmenopausal women
[2]. So far, however, the few studies that have investigated
the relationship between SHBG and breast cancer risk in
premenopausal women have failed to find an association
[34,35,38].
Genetic determinants of endogenous
hormones in relation to breast cancer risk
The genetic control of oestrogen levels has recently
received much attention and with it the notion that sus-
ceptibility to breast cancer might in part be determined
through germline polymorphisms in metabolic genes,
specifically those encoding enzymes involved in the
biosynthesis and metabolism of oestrogens [39]. Further,
it has been suggested that small effects of individual poly-
morphisms in genes involved in steroid biosynthesis and
catabolism might be cumulative [40]. Such polymorphisms
might be particularly important among postmenopausal
women, in whom oestrogen production is not homeostati-
cally controlled by pituitary gonadotrophins. Several
recent epidemiological studies have observed an associa-
tion between risk for breast cancer and polymorphisms in
genes involved in oestrogen synthesis, such as CYP17
and  CYP19, and in HSD17B1, which codes for an
enzyme that converts oestrone to oestradiol [40,41].
However, other studies have not found an association
between such polymorphisms and breast cancer, and a
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biological relationship of these polymorphisms with circu-
lating oestrogens and oestrogen metabolites has yet to be
established (reviewed in [42,43]).
Variations in oestrogen catabolism may also influence risk
for breast cancer by causing differences in the cumulative
exposure to oestrogen, by influencing the balance
between different forms of oestrogen and by altering expo-
sure to the various metabolites, some of which might have
carcinogenic properties. In humans, oestrogens are
catabolised into hydroxy-oestrogens such as 16α-hydroxy-
lated oestrogens and 2-hydroxylated (catechol) oestro-
gens, which are then converted into methoxylated
metabolites. Polymorphisms in genes such as COMT,
which is involved in the methylation of oestrogens to harm-
less metabolites, have been the subject of epidemiological
studies [44]. Several studies have found women with the
low-activity  COMT allele to be at higher risk for breast
cancer [45–47]. However, other studies have failed to find
a significant association [48,49] or have found COMT to
be important only in certain histotypes or in conjunction
with other exposures [49,50].
Exogenous oestrogens and breast cancer
In the past 50 years, exposure to exogenous oestrogens
from a variety of sources has become increasingly
common, particularly from hormonal preparations for use
as contraceptives or to combat the symptoms of the
menopause. Hormonal contraception, using oestrogens
and progestins in various forms and doses, is now one of
the most widely used forms of contraception, being taken
by 200 million women worldwide in 1996 [51]. Similarly,
the prescription of hormone replacement therapy (HRT)
for older women, containing oestrogens with or without
progestins, has become common. In Britain, for example,
33% of women aged 50–64 are current users [52]. Given
the high prevalence of exposure to these exogenous
oestrogens, even small associated increases in risk for
breast cancer could have a substantial effect on the inci-
dence of breast cancer.
Oral contraceptives and breast cancer
In 1996, data from 54 published studies on use of the
combined contraceptive pill (containing an oestrogen and
a progestogen) in relationship to breast cancer risk were
brought together in a pooled analysis [53]. Women who
were currently using combined oral contraceptives or who
had used them in the past 10 years were found to be at
slightly higher risk of having breast cancer diagnosed (rel-
ative risk [95% confidence interval] in current user, 1.24
[1.15–1.33]; 1–4 years after stopping, 1.16 [1.08–1.23];
5–9 years after stopping, 1.07 [1.02–1.13]), although the
associated cancers tended to be localised to the breast
[53]. However, there was no evidence of a significant
excess risk of having breast cancer diagnosed 10 or more
years after ceasing to use the combined contraceptive pill
(relative risk 1.01 [0.96–1.05]) [53]. More recent results
are broadly compatible with these findings, but inconsis-
tencies remain and formulations are changing; further
research is therefore crucial [54–59].
HRT and breast cancer
So far there have been more than 60 analytical studies
investigating the relationship between menopausal HRT
and breast cancer risk. Data from these studies were
brought together in a pooled analysis [7], which found that
current users of HRT, or those who ceased use 1–4 years
previously, had a 2.3% excess risk of being diagnosed
with breast cancer for each year of use, an increase in risk
that is comparable with the effect of delaying menopause
for a year [7]. The excess risk of breast cancer among
women who had used HRT for 5 years or longer was
35%. This effect was reduced after ceasing use of HRT
and had largely, if not wholly, disappeared after about
5 years. These results did not vary significantly by type of
HRT, although the collaborative study had relatively little
power to assess relationships with combined oestro-
gen–progestin therapy. More recent studies have reported
that the long-term use of preparations containing prog-
estins is more detrimental than the use of oestrogen alone
[60,61]. Recent data from three randomised controlled
trials have confirmed that exposure to oestrogens plus
progestins for 5 years is associated with an approximate
26–30% increase in risk for breast cancer [62].
Phyto-oestrogens and breast cancer
The observation that breast cancer rates are lower in most
Asian countries than in Western Europe and the USA [63]
has given risen to hypotheses about the possible protec-
tive effects of foods rich in phyto-oestrogens, particularly
soybeans, which form an important part of the diet in
several Asian countries [64]. Phyto-oestrogens are natu-
rally occurring plant compounds (or their metabolites) that
are effectively weak exogenous oestrogens because they
can mimic or modulate the actions of more potent
endogenous oestrogens, usually by binding to oestrogen
receptors (ERs) [65]. It has also been suggested that they
might reduce risk by altering oestrogen metabolism away
from the production of genotoxic metabolites [66] or
through non-oestrogenic pathways [65].
Results from numerous animal studies suggest that high
intake of soy may confer a protective effect against breast
cancer [67], but the findings from studies in humans
remain equivocal [68]. Two early case-control analyses
suggested that high levels of dietary isoflavone intake may
be protective against breast cancer in premenopausal
women [69,70], but results from later analytical studies of
adult exposure and breast cancer risk have been inconsis-
tent [68]. Two recent case-control studies have sug-
gested that a high intake of isoflavone-rich foods during
adolescence may have a protective effect on risk for
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breast cancer in adulthood [71,72]. These findings
support the possibility that exposure to phyto-oestrogens
at critical periods of development might be an important
determinant of risk for breast cancer.
The proliferative effects of oestrogen
Oestrogens have a marked proliferative effect on breast
epithelial tissue in model systems [73]. Both endogenous
and exogenous oestrogens stimulate breast epithelial cell
mitosis, increasing the number of cell divisions and thus
the opportunity for random genetic errors [1,74]. Oestro-
gen concentrations may be important at all stages in the
development of breast neoplasms because the hormonal
stimulus to cell division continues all along the progres-
sion pathway [75]. The proliferative effects of oestrogens
are brought about on entering target cells, where they
bind with a receptor protein, which then binds to hormone
response elements on the nuclear DNA, activating or sup-
pressing specific sequences in the regulatory regions of
genes responsive to oestrogen that control cell growth
and differentiation [76].
The possible role of oestrogens as mutagens in the initia-
tion of breast tumorigenesis has also received much
scrutiny. Although early experimental data suggested that
oestradiol did not have any mutagenic properties because
no mutagenic activity was found in either bacterial or
mammalian cell test systems, more recent research has
suggested that oestrogens, and to a greater extent their
metabolites including catechol oestrogens and reactive
semiquinone/quinone intermediates, may act as weak pro-
carcinogens. They might induce direct and indirect free-
radical-mediated DNA damage, genetic instability, and
mutations in cells in culture and in vivo [77]. However,
even if oestrogens can induce genetic damage, the data
overall suggest that proliferative effects are likely to be the
most important mechanism by which this hormone acts to
influence the development of breast cancer.
It has also been suggested that oestrogens might have an
important influence on risk for developing breast cancer
through effects before the initiation of the disease [78].
Raised oestrogen levels during fetal life have been shown
to influence morphology of the mammary gland [79], and
increased levels are also thought to be responsible for the
persistence of epithelial structures (terminal end buds)
that are known to be sites of malignant transformation
[80]. Furthermore, results from animal models and indirect
human evidence indicate that exposure to elevated oestro-
gen levels in utero may increase the risk for developing
breast cancer in adulthood [79,81].
Epidemiological studies investigating the relationship
between breast cancer risk and oestrogen exposure in
utero have examined several perinatal factors, such as
high birth weight [82,83]. In six out of seven epidemiologi-
cal studies, birth weight has been found to be positively
associated with risk for breast cancer [82,84], although
several studies have also found low birth weight (less than
2500g) to be associated with a higher risk for breast
cancer [84]. This intriguing field relates to the suggestion
that certain perinatal factors are associated with high con-
centrations of maternal oestrogens in pregnancy [78] or
high levels of oestrogens in the infant postnatally [85].
However, these associations remain to be confirmed [86].
Sensitivity to oestrogen
The sensitivity of breast tissue to oestrogen is dependent
on the levels and types of ERs [76] and it is possible that
variation in breast cancer risk is, in part, attributable to
inter-individual variation in receptor levels in normal breast
tissue [87]. ER levels have been found to vary by age,
menopausal status and perhaps by ethnic group [88,89].
Sensitivity of breast tissue to oestrogens might also be
determined by the balance between the two ER types,
ER-α and ER-β. ER-β has a lower affinity for oestrogen
than ER-α and may decrease the sensitivity of ER-α to
oestrogen [90].
Other hormones and breast cancer risk
Whereas early hypotheses focused on oestrogens as
important hormonal determinants of breast cancer risk
[91], current epidemiological and experimental data indi-
cate that other hormones, such as progesterone [1], pro-
lactin [5] and testosterone [6], are also important in the
aetiology of breast cancer.
It has been proposed that progesterone augments the
effects of oestrogens on breast cancer development [1],
and this hypothesis has gained support from several lines
of evidence. Breast cell proliferation has been found to be
greatest during the luteal phase of the menstrual cycle [1],
when levels of progesterone are at their highest, and a
cross-sectional study of women undergoing breast biop-
sies found that the mitotic activity in the terminal ductal
lobular unit of the breast was greater in women taking
combined hormone preparations than in women using
oestrogen alone [92]. Furthermore, recent data indicate
that hormone replacement therapies containing both
oestrogens and progestogens have a greater detrimental
effect on risk for breast cancer than preparations contain-
ing oestrogens alone [61]. Progestins, like oestrogens, are
thought to exert their effects mainly through binding to
nuclear receptor proteins.
Epidemiological studies of prolactin have found that circu-
lating levels of the hormone are correlated with some
established risk factors for breast cancer; for example,
concentrations are higher in nulliparous than parous
women [93] and higher among women using certain types
of oral contraceptives than among those who were not
[94,95]. High concentrations of prolactin have also been
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found to be associated with increased risk for breast
cancer in prospective studies in postmenopausal women
[5]. In the largest prospective study so far, more than a
doubling in risk for breast cancer was observed among
women in the highest 25% of the prolactin distribution rel-
ative to those in the lowest 25%, independent of the
effects of concentrations of circulating oestrogens, andro-
gens and insulin-like growth factor-1 [96]. Prolactin, pro-
duced at the endocrine and autocrine/paracrine levels,
acts to stimulate the proliferation, survival and motility of
mammary epithelial cells through its interaction with
receptors at the cell surface [5].
Testosterone might also have a role in the aetiology of
breast cancer [6]. Results from a recent pooled analysis of
prospective studies in postmenopausal women estimated
that breast cancer risk among women in the top quintile of
exposure to endogenous testosterone was more than
double that of women in the lowest quintile [2]. However,
the mechanisms by which testosterone might influence
the risk for developing breast cancer remain unclear, as do
the effects of the androgen on the risk for premenopausal
breast cancer [6]. It may be that, in postmenopausal
women at least, testosterone is converted to oestrogen in
the breast.
Preventive strategies
The epidemiological evidence suggests that the risk of
breast cancer might be reduced by lowering lifetime expo-
sure to oestrogens through changes in lifestyle and repro-
ductive behaviour. At present the only clear
oestrogen-related risk factor for breast cancer that is
amenable to change is obesity after the menopause. Thus,
prudent advice is to maintain weight such that body mass
is below 25kg/m2. Other lifestyle changes that may have
protective effects mediated by oestrogens include min-
imising alcohol consumption and taking regular physical
exercise. Recent data suggest, too, that long-term use of
HRT should be avoided, unless there are strong clinical
indications. Voluntary changes in most of the important
reproductive risk factors such as parity and ages at men-
arche and menopause are not realistic, but extended
breast feeding will produce a small decrease in breast
cancer risk, in addition to its benefits for the child.
More radical measures including surgery, such as bilateral
prophylactic oophorectomy and/or mastectomy, or chemo-
prophylaxis may be considered for particularly susceptible
subgroups, such as those with a family history of breast
cancer or characteristics predisposing them to exposure
to high oestrogen levels. Bilateral oophorectomy has been
found to result in a 50–70% reduction in breast cancer
risk [97] although, in general, studies have focused only
on women with mutations in BRCA1/BRCA2. Trial data
show that the partial ER agonist tamoxifen and other ER
modulators such as raloxifene [98] reduce the incidence
of primary ER-positive breast cancer [3,99]. Aromatase
inhibitors [100], which suppress the peripheral conversion
of androstenedione to oestradiol through inhibition of the
aromatase enzyme, and agonists of gonadotrophin-releas-
ing hormone, which suppress ovarian function in pre-
menopausal women, have been shown to be effective in
the treatment of early breast cancer [101] and may be
developed for chemoprevention [1].
As these chemopreventatives may themselves be associ-
ated with detrimental effects, clinicians try to identify
women at particularly high risk for breast cancer, for whom
benefits of such interventions are likely to outweigh the
risks [102,103]. One method of identifying women at high
risk for the disease is to use mathematical models; one
such tool is the Gail model, which uses data on risk
factors to predict individualised risk for breast cancer
[104].
Conclusion
Oestrogens have a key role in the aetiology of breast
cancer, probably because of their proliferative effects.
Current data suggest that these steroid hormones
mediate the relationship between breast cancer and many
established risk factors, such as age at menarche, age at
menopause, and obesity in postmenopausal women.
However, the effects of other risk factors, such as parity
and breast feeding, may not be explained only by oestro-
gens; other hormones such as progesterone, prolactin
and testosterone may also be important. More work is
needed to clarify the effects of hormones on risk for breast
cancer and the mechanisms involved, as well as to unravel
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